Clinicopathological features and trend changes of gastric carcinoma in Southern China

Table 1 Age and sex n (%)

Age	Male	Female	Total	P value
Age Group
≤ 40	91 (4.33)	122 (5.81)	213 (10.14)
40-49	196 (9.33)	136 (6.48)	332 (15.81)
50-59	412 (19.62)	181 (8.62)	593 (28.24)
≥ 60	716 (34.10)	246 (11.71)	962 (45.81)	< 0.001
Number of periods
1994-1999	278 (13.24)	106 (5.05)	384 (18.29)
2000-2005	407 (19.38)	216 (10.29)	623 (29.67)
2006-2013	730 (34.76)	363 (17.29)	1093 (52.05)	0.056
Total	1415 (67.38)	685 (32.62)	2100 (100)
Mean ± SD age (yr)	58.69 ± 11.34	53.49 ± 13.73	57.00 ± 12.41
Mean age of periods
1994-1999	58.97 ± 10.87	53.99 ± 14.14	57.59 ± 12.05
2000-2005	58.08 ± 11.84	51.78 ± 13.72	55.90 ± 12.87
2006-2013	58.93 ± 11.23	54.36 ± 13.56	57.41 ± 12.24

Table 2 Morphologic features n (%)

Size (cm)	Mean ± SD	5.57 ± 3.43
	0-2.0	269 (12.81)
	2.1-5.0	969 (46.14)
	5.1-10	723 (34.43)
	> 10	139 (6.62)
Location	Cardia/EGJ	483 (23.00)
	Fundus/body	524 (24.95)
	Antrum	936 (44.57)
	Diffuse	75 (3.57)
	Remnant	74 (3.52)
	Multiple	8 (0.38)
Borrmann type	I	97 (4.62)
	II	510 (24.29)
	III	1252 (59.62)
	IV	241 (11.48)
Pathologic type	Tubular/papillary adenocarcinoma	1617 (79.57)
	Mucinous carcinoma	127 (6.05)
	Signet cell carcinoma	255 (12.14)
	Neuroendocrine neoplasm	9 (0.43)
	Squamous carcinoma	32 (1.52)
	Others	6 (0.29)
Differentiation	Well	87 (4.14)
	Moderate	613 (29.19)
	Poor	1400 (66.67)

Table 3 pTNM stage and time periods

Stage	1994-1999	2000-2005	2006-2013	Total	P value
0	1	1	10	12 (0.57%)
Ia	10	56	105	171 (8.14%)
Ib	17	54	88	159 (7.57%)
IIa	35	89	133	257 (12.24%)
IIb	61	132	193	386 (18.38%)
IIIa	90	75	134	299 (14.24%)
IIIb	57	45	109	211 (10.05%)
IIIc	24	9	85	118 (5.62%)
IV	89	162	236	487 (23.19%)
Total	384	623	1093	2100	< 0.001

Table 4 Clinicopathological features of different ages n (%)

		≤ 40 yr	40-49 yr	50-59 yr	≥ 60 yr
Size (cm)	Mean ± SD	5.83 ± 4.03	5.96 ± 3.95	5.38 ± 3.27	5.49 ± 3.17	< 0.001
	0-2.0	34 (1.62)	44 (2.10)	80 (3.81)	111 (5.29)
	2.1-5.0	88 (4.19)	140 (6.67)	290 (13.81)	451 (21.48)
	5.1-10	69 (3.29)	119 (5.67)	183 (8.71)	352 (16.76)
	> 10	22 (1.05)	29 (1.38)	40 (1.90)	48 (2.29)	0.013
Location	Cardia/GEJ	21 (1.00)	47 (2.24)	146 (6.95)	269 (12.81)
	Fundus/body	77 (3.67)	101 (4.81)	148 (7.05)	198 (9.43)
	Antrum	103 (4.9)	162 (7.71)	258 (12.29)	413 (19.67)
	Diffuse	9 (0.43)	18 (0.86)	25 (1.19)	23 (1.10)
	Remnant	2 (0.10)	3 (0.14)	15 (0.71)	54 (2.57)
	Multiple	1 (0.05)	1 (0.05)	1 (0.05)	5 (0.24)	< 0.001
Borrmann type	I	10 (0.48)	8 (0.38)	37 (1.76)	59 (2.81)
	II	48 (2.29)	84 (4.00)	146 (6.95)	229 (10.90)
	III	116 (5.52)	179 (8.52)	335 (15.95)	605 (27.86)
	IV	39 (1.86)	61 (2.90)	75 (3.57)	89 (4.24)	< 0.001
Pathologic type	Tubular or papillary adenocarcinoma	164 (7.81)	265 (12.62)	456 (21.71)	786 (37.43)
	Mucinous carcinoma	9 (0.43)	12 (0.57)	36 (1.71)	70 (3.33)
	Signet cell carcinoma	37 (1.76)	48 (2.29)	91 (4.33)	79 (3.76)
	Neuroendocrine neoplasm	0 (0.00)	2 (0.10)	2 (0.10)	5 (0.24)
	Squamous carcinoma	3 (0.14)	5 (0.24)	6 (0.29)	18 (0.86)	0.001
	Others	0 (0.00)	0 (0.00)	2 (0.10)	4 (0.19)
Differentiation	Well	5 (0.24)	8 (0.38)	23 (1.10)	51 (2.43)
	Moderate	15 (0.71)	66 (3.14)	169 (8.05)	363 (17.29)
	Poor	193 (9.19)	258 (12.29)	401 (19.10)	548 (26.10)	< 0.001
pTNM stage	0	1 (0.05)	1 (0.05)	1 (0.05)	9 (0.43)
	Ia	21 (1.00)	27 (1.29)	48 (2.29)	75 (3.57)
	Ib	14 (0.67)	31 (1.48)	56 (2.67)	58 (2.76)
	IIa	25 (1.19)	33 (1.57)	82 (3.90)	117 (5.57)
	IIb	29 (1.38)	53 (2.52)	99 (4.71)	205 (9.76)
	IIIa	29 (1.38)	35 (1.67)	80 (3.81)	155 (7.38)
	IIIb	18 (0.86)	36 (1.71)	65 ( 3.10)	92 (4.38)
	IIIc	11 (0.52)	23 (1.10)	29 (1.38)	55 (2.62)
	IV	65 (3.10)	93 (4.43)	133 (6.33)	196 (9.33)	0.006
Metastasis	M0	148 (7.05)	239 (11.38)	460 (21.90)	766 (36.48)
	M1	65 (3.10)	93 (4.43)	133 (6.33)	196 (9.33)	0.002